Fig. 1 · Structure

Documents & Downloads

C646

Cat. No. A12815 CAS 328968-36-1

p300/CBP inhibitor

C646 is a selective p300/CREB-binding protein (CBP) inhibitor (Ki = 400 nM).

In Stock

Publications for C646

2 publications citing this product

  1. Thibaud Reyser, .et al. , Pharmaceutics, 2023, Oct 10;15(10):2440 PMID: 37896200
  2. Zhifeng Zhang, .et al. , PLoS One, 2017, 12(10): e0186900 PMID: 29049411

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

C646 inhibited purified p300 histone acetyltransferase competitively with acetyl-CoA (reported Ki 400 nM) and noncompetitively with the H4-15 peptide substrate. These biochemical results describe the tested C646 preparation and do not establish cellular target specificity or potency for an isolated geometric isomer. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
p300/CBP (Cell-free assay) Ki 400 nM

Cellular Effect

Cell Line Activity Value Description Reference
MCF7 IC50 26.09 μM Antiproliferative activity against HER2-negative human MCF7 cells measured after 6 days of incubation by sulforhodamine B assay [PMID: 31306905]
T47D IC50 7.8 μM Antiproliferative activity against HER2-negative human T47D cells measured after 6 days of incubation by sulforhodamine B assay [PMID: 31306905]

In Vitro Studies

Substrate-dependent inhibition of purified p300 HAT

Biochemical assay · Purified semisynthetic p300 histone acetyltransferase domain with H4-15 peptide and acetyl-CoA substrates [1]

Direct radiometric assays supported competitive inhibition with respect to acetyl-CoA and noncompetitive inhibition with respect to H4-15 peptide. These are purified-enzyme kinetic findings; they do not establish a unique cellular target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p300 inhibition with acetyl-CoA varied and H4-15 fixed at 100 μMKi 400 ± 60 nM[1]
p300 inhibition with H4-15 peptide varied and acetyl-CoA fixed at 10 μMKi 530 ± 40 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Three inhibitor conditions: 0, 0.5×IC50 and IC50; exact molar inhibitor concentrations for these kinetic series are not supplied in the retrieved method text.
Exposure duration
Enzyme concentration and reaction time were varied to keep substrate turnover below 10%; no single duration assigned to all kinetic series.
Method
Radiolabeled acetyl transfer to H4-15, electrophoretic separation and phosphorimage quantification; acetyl-CoA varied from 5–120 μM or peptide from 25–500 μM. Assays performed in duplicate.
Vehicle
DMSO, held constant (<5%) in the referenced direct-assay procedure.
Reported limits
Meaning of caption ± values and number of independent enzyme preparations not specified in the read locations. Figure images and SI not retrieved; no curve-derived values or SI selectivity results adopted.
Methods and source locations

Compound reported in the paper: C646; Compound label in the paper: ChemBridge #5838646

Applies to the reported C646 preparation at parent-compound level, not an isolated stereoisomer, salt conversion, or validation of an Adooq lot.

Results: Mechanism of p300 inhibition; Figure 1B–C caption; Experimental Procedures: Kinetic characterization of verified inhibitors and analogs (BioC passages 15, 57–58, 77)

p300 inhibition with acetyl-CoA varied and H4-15 fixed at 100 μM: Direct 14C-acetyl transfer assay; global fitting of substrate-dependent initial rates. Competitive pattern versus acetyl-CoA. The Figure 1 caption does not define the meaning of ±. — Figure 1B caption; Results: Mechanism of p300 inhibition; Experimental Procedures: Kinetic characterization (passages 15, 58, 77)

p300 inhibition with H4-15 peptide varied and acetyl-CoA fixed at 10 μM: Direct 14C-acetyl transfer assay; noncompetitive pattern versus H4-15. Figure 1 caption reports ± without defining its meaning. — Figure 1C caption; Experimental Procedures: Kinetic characterization (passages 58, 77)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 328968-36-1
Applications p300/CBP inhibitor
Formula C24H19N3O6
Molecular Weight 445.42
SMILES
CC1=C(C=C(C(=C1)C2=CC=C(O2)/C=C\3/C(=NN(C3=O)C4=CC=C(C=C4)C(=O)O)C)[N+](=O)[O-])C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 13 mg/mL (29.18 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
5% DMSO+40% PEG 300+5%Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Bowers EM, Yan G, Mukherjee C, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chemistry & Biology (2010). PMID: 20534345 DOI: 10.1016/j.chembiol.2010.03.006 Source material

Publications

2 publications citing this product

  1. Thibaud Reyser, .et al. , Pharmaceutics, 2023, Oct 10;15(10):2440 PMID: 37896200
  2. Zhifeng Zhang, .et al. , PLoS One, 2017, 12(10): e0186900 PMID: 29049411

Added to your cart

View Cart Checkout
Loading...